Stock Information
Corcept Therapeutics Inc (CORT)
Ticker Symbol: CORT
Exchange: NASDAQ
Sector: Pharmaceuticals
Market Cap: $4,469.45 mil
Piotroski score: 6
PE Ratio: 46.7012
EPS (TTM): 0.8303
Revenue (TTM): $6.34 M
Dividend Yield: N/A%
ROE: 15.34%
Latest News
-
Did Lifyorli’s Landmark Ovarian Cancer Data and NCCN Nod Just Shift Corcept Therapeutics’ (CORT) Investment Narrative?
Mon, Apr 13, 2026 11:10 AM
-
How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates
Sun, Apr 12, 2026 6:10 AM
-
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Fri, Apr 10, 2026 8:45 PM
-
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Fri, Apr 10, 2026 8:38 PM
-
Corcept Therapeutics Presents Final Overall Survival Data From Its Pivotal Phase 3 ROSELLA Trial Of Lifyorli Combined With The Chemotherapeutic Agent Nab-Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer In A Late-Breaking Oral Presentation At The Society Of Gynecologic Oncology 2026 Annual Meeting On Women's Cancer; Data Demonstrate A 35 Percent Reduction In Risk Of Death
Fri, Apr 10, 2026 4:53 PM
Key Financials
Financial data not available
